Nelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic Cancer

Inclusion criteria

DISEASE CHARACTERISTICS: * Diagnosed with advanced hematologic malignancies meeting the following criteria: * Multiple myeloma * Received ≥ 2 lines of prior chemotherapy (induction chemotherapy followed by high-dose chemotherapy and autologous stem cell transplant with or without maintenance therapy is considered one line of therapy) * Acute myeloid leukemia * Acute lymphoblastic leukemia * Diffuse large B-cell lymphoma * Hodgkin lymphoma * Mantle cell lymphoma * Mature T- and NK-cell neoplasms restricted to the following WHO-defined entities: * T-cell prolymphocytic leukemia * T-cell large granular lymphocytic leukemia * Aggressive NK-cell leukemia * Adult T-cell leukemia/lymphoma * Extranodal NK/T-cell lymphoma (nasal type) * Mycosis fungoides * Sézary syndrome * Primary CD30-positive T-cell lymphoproliferative disorders * Primary cutaneous anaplastic large cell lymphoma * Primary cutaneous gamma-delta T-cell lymphoma * Peripheral T-cell lymphoma (not otherwise specified) * Angioimmunoblastic T-cell lymphoma * Anaplastic large cell lymphoma (ALK-positive/ALK-negative) * Grade 3B follicular lymphoma * Relapsed following or progressed during standard therapy * Meeting the following criteria: * Standard intensive therapy is not feasible * Current disease state for which there is no standard effective therapy * Refused standard therapy where no curative option exists * Measurable disease, defined as the following: * Myeloma: measurable serum monoclonal protein \> 1 g/dL for IgG, or \> 0.5 g/dL for IgA, IgM or IgD, or difference between involved and uninvolved free light chain levels in serum \> 100 mg/L * Lymphoma: must have ≥ 1 lesion measurable by CT (longest diameter ≥ 15 mm) * Acute leukemia: ≥ 20% blasts in bone marrow or in peripheral blood (≥ 200/mL blasts in peripheral blood) * No HIV-associated lymphoma PATIENT CHARACTERISTICS: * WHO performance status 0-2 * Absolute neutrophil count ≥ 1,500/mm³ * Platelet count ≥ 75,000/mm³ (if bone marrow impairment, ≥ 20,000/mm\^3) * Hemoglobin \> 80 g/L (if considered to be caused by the underlying hematologic malignancy or bone marrow impairment, \> 80 g/L after transfusion) * Bilirubin ≤ 1.5 times upper limit of normal (ULN) (if suspected hemolysis, direct bilirubin ≤ 1.5 times ULN) * ALT ≤ 2.5 times ULN * Calculated creatinine clearance \> 30 mL/min * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for 12 months after completion of study treatment * Willing and capable to comply with an oral regimen * Capable of understanding information given by the investigator on the trial * Able to adhere and remain in geographic proximity to allow proper staging, treatment, and followup * No other non-hematologic malignancy within the past 5 years, except adequately treated cervical carcinoma in situ or localized nonmelanoma skin cancer * No known chronic hepatitis B or C infection or known HIV infection * No serious underlying medical condition (at the judgment of the investigator) which would impair the ability of the patient to participate in the trial, including any of the following: * Active autoimmune disease * Uncontrolled diabetes * Ongoing or active infection * Symptomatic congestive heart failure * Unstable angina pectoris * Cardiac arrhythmia * Psychiatric disorder * No myocardial infarction within the past 6 months * No polyneuropathy \> grade 1 significantly interfering with activities of daily living or painful polyneuropathy * No known hypersensitivity to trial drugs or hypersensitivity to any other component of the trial drugs PRIOR CONCURRENT THERAPY: * See Disease Characteristics * No more than 4 prior lines of chemotherapeutic regimens (induction chemotherapy followed by high-dose chemotherapy and autologous stem cell transplant with or without maintenance therapy is considered one line of therapy) * More than 30 days since prior treatment in a clinical trial * More than 30 days since prior and no concurrent chemotherapy or biologic agents * For patients with acute leukemia, hydroxyurea may be given up to 48 hours before first administration of the trial treatment, and low dose cytarabine (up to 20 mg/m\^2) and mitoxantrone up to 20 mg up to 14 days before first dosing * At least 1 week since prior and no concurrent CYP3A4 modulators * No concurrent other experimental drugs * No concurrent radiotherapy * No concurrent antineoplastic therapy with chemotherapeutic or biologic agents